AKIGAI has discovered that EGFR inhibitors act as an “off switch” for neuropathic pain (NP) in roughly 70% of patients by targeting damaged pain fibers while sparing the central nervous system. Its lead candidate, AKI007, is a dosereduced, reformulated tablet with four layers of market protection. The company plans to advance AKI007 into a Phase III trial in Complex Regional Pain Syndrome (CRPS) in 2026, alongside a Phase II basket study across additional NP indications.

DoMore Diagnostics uses AI-driven digital biomarkers to guide personalized treatment decisions. Its technology predicts patient outcomes directly from routine tumor tissue slides and integrates seamlessly into existing pathology workflows. The lead product, Histotype Px® Colorectal, is a CE‑marked biomarker for Stage II and III colorectal cancer that informs adjuvant chemotherapy decisions after surgical resection.

ImmunoQuest Therapeutics is a preclinical biotechnology company developing next‑generation ADCs targeting p95HER2, a tumor‑specific HER2 isoform that drives metastasis and resistance to HER2 therapies. The company’s lead program, NAZ‑001, is a first‑in‑class ADC designed to deliver potent cytotoxic payloads with precision across HER2‑altered tumors where current therapies fail.

Node Pharma is a Norwegian radiopharmaceutical company developing first‑in‑class alpha therapies for cancer patients with limited treatment options. Its lead candidate, NODE101, uses a transarterial nanomedicine approach to deliver Radium‑223 directly to liver tumors, aiming for greater precision and safety than current beta‑based therapies. The company is advancing toward a Phase 1 clinical study in 2026 and building a scalable platform with global potential.

Rab Diagnostics develops precision biomarker solutions to support nextgeneration targeted chemotherapies, including ADCs. Its proprietary RabCancer platform establishes a new standard for predicting response to ADC therapy. Leveraging deep expertise in intracellular drug trafficking, Rab partners with biopharma companies to accelerate clinical development and deliver precision diagnostics to cancer patients.

ROPCA is transforming arthritis imaging with a robotic, AI‑driven self‑service ultrasound station that automates exams, removes operator dependency, and delivers consistent, high‑quality imaging. The system is already in paid use at the Mayo Clinic and with key opinion leaders across Germany, Austria, and Denmark. The company is targeting FDA clearance in the first half of next year, alongside a planned VA test agreement to support broader U.S. adoption.

Thelper AS has developed binders targeting a viral‑derived protein that is highly and selectively expressed in aggressive cancers. These binders enable the creation of highly potent precision medicines with improved safety profiles compared to existing therapies. The company is building a platform of first‑ and best‑in‑class targeted oncology therapeutics while maintaining a focus on cost‑efficiency and early exit opportunities for investors. 

Tribune Therapeutics is a Scandinavian preclinical biotech company developing novel treatments for fibrotic diseases. Its lead compound targets the CCN protein family, overcoming historical challenges that limited earlier therapeutic approaches. The program demonstrates broad efficacy in kidney and lung models, supported by a clear biomarker strategy for upcoming clinical trials. Tribune has raised EUR 37M from leading Nordic and UK investors.